


THIRD ANNUAL  
TRANSLATIONAL CANCER MEDICINE SYMPOSIUM



Mesothelioma-Melanoma Cancer Syndrome:  
**Gene-Environment  
Interaction?**

Friday, December 2, 2011  
The Queen's Conference Center  
Honolulu, Hawaii



**DISTINGUISHED GUEST FACULTY**  
**Harald zur Hausen, MD**  
*2008 Nobel Prize Recipient  
in Physiology & Medicine*



UNIVERSITY OF HAWAI'I  
CANCER CENTER



**THE QUEEN'S  
MEDICAL CENTER**

**It is with great pleasure that I invite you to meet the Weinman's cancer distinguished researchers at the 3<sup>rd</sup> Annual Translational Cancer Medicine Symposium. This symposium will discuss the newly discovered Mesothelioma-Melanoma Cancer Syndrome.**

This hereditary cancer syndrome is caused by heterozygous germline mutations of the *BAP1* gene and characterized by the development of melanocytic nevi, melanoma, uveal melanoma, mesothelioma and possibly other cancers. The research that led to this new breakthrough in molecular cancer genetics was published in two separate articles this past August 2011 in *Nature Genetics*. In these articles scientists at the University of Graz (Austria) and Memorial Sloan Kettering Cancer Center (New York) made the link to melanocytic nevi and melanoma, while a research team led by investigators at the University of Hawaii Cancer Center made the link to uveal melanoma and mesothelioma.

Physicians and scientists who made this discovery and some of the leading experts in cancer and the *BAP1* gene, will gather for the first time in Honolulu to discuss how this discovery will help us implement novel preventive, early detection and therapeutic strategies for these malignancies.

We are also honored to welcome Carlo Maria Croce, M.D., a member of the US National Academy of Sciences and one of the scientists who started the field of molecular cancer genetics. His discoveries have led to revolutionary innovations in the development of novel approaches to cancer prevention, diagnosis, monitoring and treatment, based on gene-target discovery, verification and rational drug development. More recently he discovered the role of a new class of cancer genes encoding microRNAs which will be the topic of his keynote address.

This symposium has been designed for researchers and clinicians who deal with cancer patients, as well as medical students and residents. It will stimulate mutual interactions among leading researchers and clinicians. We hope that this will result in multidisciplinary teams that include dermatologists, pathologists, ophthalmologists, molecular geneticists, oncologists and surgeons working together to first identify and then prevent or treat the different types of cancers that develop in *BAP1* mutant carriers in the early stages when they are much more susceptible to medical intervention.

Together, we continue a dialogue that started 2 years ago with the establishment of the Hawaii Cancer Consortium and that has already facilitated a major breakthrough in cancer research. The University of Hawaii Cancer Center, with its prestigious National Cancer Institute designation as one of the only 66 in the U.S., and the hospitals across the State of Hawaii that provide excellent clinical cancer care are working together to make Hawaii a state where cutting edge cancer research is conducted and cutting edge clinical cancer care is provided."

*Join us!*

*Michele Carbone, MD, PhD  
Symposium Chair*



UNIVERSITY OF HAWAII  
CANCER CENTER



**THE QUEEN'S  
MEDICAL CENTER**

# Mesothelioma-Melanoma Cancer Syndrome: Gene-Environment Interaction?

## Program

- 7:30 am      *Registration • Coffee / Tea*
- 8:15 am      **Welcome & Opening Remarks**  
Virginia Hinshaw, PhD  
*University of Hawaii at Manoa*  
Arthur Ushijima  
*The Queen's Medical Center*  
Michele Carbone, MD, PhD  
*University of Hawaii Cancer Center*  
Barry & Virginia Weinman  
*The Weinman Foundation*
- 
- Session I: Mesothelioma-Melanoma, A New Cancer Syndrome**  
*Session Chair: Mark Clanton, MD, MPH*
- 8:45 am      **Gene-Environment Interactions and Public Health**  
*Mark Clanton, MD, MPH*
- 9:00 am      **BAP1: Molecular and Biological Activities**  
*Frank J. Rauscher, III, PhD*
- 9:25 am      **The Discovery of the Mesothelioma-Uveal Melanoma Cancer Syndrome: From the Cappadocian Villages to Molecular Genetics**  
*Michele Carbone, MD, PhD*
- 9:50 am      **Sporadic and Germline BAP1 Mutations in Uveal and Cutaneous Melanoma: New Insights into Cancer Evolution**  
*J. William Harbour, MD*
- 10:15 am     *Break*
- 
- Session II: Biology of Mutated BAP1**  
*Session Chair: Giovanni Gaudino, PhD*
- 10:25 am     **Discovery of BAP1-Germline Mutations in Families with Melanocytic Tumors and Consequences for Genetic Counseling**  
*Michael R. Speicher, MD*
- 10:50 am     **Progress in the Development of a Mouse Model Designed to Recapitulate BAP1-Related Mesothelioma Susceptibility**  
*Joseph R. Testa, PhD, FACMG*
- 
- 11:15 am     **Keynote Address: Role of MicroRNAs in Cancer**  
*Carlo M. Croce, MD*  
Discovered almost 10 years ago, microRNAs are now considered one of the most important mechanisms in carcinogenesis. MicroRNAs have been widely recognized as innovative targets and pharmaceutical tools to fight cancer. Dr. Croce is universally appreciated in the scientific community as the worldwide leader in microRNA research on cancer.
- 12:00 Noon   *Lunch*

# Mesothelioma-Melanoma Cancer Syndrome: Gene-Environment Interaction?

---

## **Session III: Epidemiology of BAP1**

*Session Chair: Herbert Yu, MD, PhD*

12:45 pm The Role of BAP1 in Tumorigenesis From An Epidemiology Perspective

*Xifeng Wu, MD, PhD*

1:10 pm BAP1 Mutations: Key Questions and Future Directions

*Alisa M. Goldstein PhD*

1:35 pm *Break*

---

## **Session IV: BAP1 From the Bench to the Bedside**

*Session Chair: Mark Clanton, MD, MPH*

1:50 pm Potential Targets for Mesothelioma Prevention and Therapy

*Haining Yang, PhD*

2:15 pm Signaling Pathways in Melanoma: Where Could BAP1 Fit?

*Elizabeth A. Grimm, PhD*

2:40 pm Loss of BAP1 in Melanocytic Tumors: Clinical and Histological Aspects

*Thomas Wiesner, MD*

3:05 pm Clinical Implications of the BAP1 Germline Mutations: Opportunities for Early Detection and Therapy

*Harvey A. Pass, MD, FACS*

---

## **Session V: Panel Discussion**

*Session Moderator: Jack A. Roth, MD, FACS*

3:30 pm The discovery that germline BAP1 mutations predispose to the development of mesothelioma, uveal melanoma, melanocytic tumors and other types of cancer, provides physicians with a new tool to identify individuals at very high risk of developing these types of cancers. The objective of the panel discussion is to discuss opportunities for prevention, early detection and therapy.

*Panelists: Symposium Presenters, Chairs and*

*Neal H. Atebara, MD*

*Peter Bryant-Greenwood, MD, MBA, FCAP*

*Gregg T. Kokame, MD*

*Paul T. Morris, MD, FACS*

*Luciano Mutti, MD, PhD*

*Thomas Slavin Jr., MD, FAAP*

4:30 pm *Adjourn*

## Distinguished Guest Faculty



### **Carlo M. Croce, MD**

*Weinman Foundation Innovators in Cancer Research*  
The John W. Wolfe Chair, Human Cancer Genetics  
Director, Institute of Genetics  
Chairman and Professor, Department of Molecular Virology,  
Immunology, and Medical Genetics  
Director, Human Cancer Genetics Program  
The Ohio State University  
Columbus, Ohio

## Faculty

### **Neal H. Atebara, MD**

*Assistant Clinical Professor, Ophthalmology*  
University of Hawaii John A. Burns School of Medicine  
Honolulu, Hawaii

### **Peter Bryant-Greenwood, MD, MBA, FCAP**

*Vice Chair & Assistant Professor, Department of Pathology*  
University of Hawaii John A. Burns School of Medicine  
Director, Pathology Services  
The Queen's Medical Center  
Honolulu, Hawaii

### **Michele Carbone, MD, PhD**

*Director*  
University of Hawaii Cancer Center  
Professor and Chair, Department of Pathology  
University of Hawaii John A. Burns School of Medicine  
Honolulu, Hawaii

### **Mark Clanton, MD, MPH**

*Chief Medical Officer, High Plains Division*  
American Cancer Society  
Austin, Texas

### **Giovanni Gaudino, PhD**

*Professor*  
University of Hawaii Cancer Center  
Honolulu, Hawaii

### **Alisa M. Goldstein, PhD**

*Senior Investigator*  
Division of Cancer Epidemiology & Genetics  
National Cancer Institute  
Bethesda, Maryland

### **Elizabeth A. Grimm, PhD**

*Deputy Division Head for Research Affairs*  
Professor, Department of Melanoma Medical Oncology -  
Research  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

### **J. William Harbour, MD**

*Paul A. Cibis Distinguished Professor of Ophthalmology*  
Professor of Cell Biology & Physiology  
Professor of Medicine/Molecular Oncology  
Washington University School of Medicine  
St. Louis, Missouri

### **Gregg T. Kokame, MD**

*Clinical Professor, Ophthalmology*  
University of Hawaii John A. Burns School of Medicine  
Honolulu, Hawaii

### **Paul T. Morris, MD, FACS**

*Assistant Professor, General Surgery*  
Department of Surgery  
University of Hawaii John A. Burns School of Medicine  
Chief, Department of Surgery  
The Queen's Medical Center  
Honolulu, Hawaii

### **Luciano Mutti, MD, PhD**

*Head, Department of Medicine*  
Vercelli Teaching Hospital  
Scientific Director, Lab of Clinical Oncology  
Local Health Authority Vercelli  
Piedmont (Vercelli), Italy

## Faculty (cont.)

### **Harvey I. Pass, MD, FACS**

*Stephen E. Banner Professor Thoracic Oncology  
Division Chief of General Thoracic Surgery  
Department of Cardiothoracic Surgery  
Vice Chair for Research  
NYU Langone Medical Center  
New York, New York*

### **Frank J. Rauscher III, PhD**

*Professor and Founder, Gene Expression and Regulation  
Program  
Deputy Director for Basic Science  
The Wistar Institute Cancer Center  
Wistar Institute Professor of Genetics  
The University of Pennsylvania School of Medicine  
Philadelphia, Pennsylvania*

### **Jack A. Roth, MD, FACS**

*Professor and Bud Johnson Clinical Distinguished Chair  
Professor of Molecular and Cellular Oncology  
Director, W. M. Keck Center for Innovative Cancer  
Therapies  
Chief, Section of Thoracic Molecular Oncology  
Department of Thoracic & Cardiovascular Surgery  
The University of Texas MD Anderson Cancer Center  
Houston, Texas*

### **Thomas Slavin, Jr., MD, FAAP**

*Assistant Professor  
Department of Pediatrics  
University of Hawaii John A. Burns School of Medicine  
Clinical Geneticist, Hawaii Community Genetics  
Honolulu, Hawaii*

### **Michael R. Speicher, MD**

*Chair of Institute  
Institute of Human Genetics  
Medical University of Graz  
Graz, Austria*

### **Joseph R. Testa, PhD, FACMG**

*Chair, Mesothelioma Working Group  
Co-Leader, Cancer Biology  
Scientific Leader, Personalized Kidney Cancer Therapy  
Keystone  
Director, Genomics Facility  
Fox Chase Cancer Center  
Philadelphia, Pennsylvania*

### **Thomas Wiesner, MD**

*Research Fellow  
Human Oncology & Pathogenesis Program  
Memorial Sloan Kettering Cancer Center  
New York, New York*

### **Xifeng Wu, MD, PhD**

*Professor and Chair, Department of Epidemiology  
Director, Center for Translational and Public Health  
Genomics  
The University of Texas MD Anderson Cancer Center  
Houston, Texas*

### **Haining Yang, PhD**

*Assistant Professor  
University of Hawaii Cancer Center  
University of Hawaii John A. Burns School of Medicine  
Honolulu, Hawaii*

### **Herbert Yu, MD, PhD**

*Professor, Department of Epidemiology (Chronic  
Diseases)  
School of Public Health  
Yale University  
New Haven, Connecticut*

## Educational Objectives

At the end of this symposium, participants will be able to:

- Describe the new *BAP1*-related cancer syndrome; and identify characteristics of individuals with this condition.
- Discuss functions of the *BAP1* gene and its role in tumor development.
- Explore the embryology, histology and pathology of mesothelial cells/mesothelioma and uveal melanocytes/uveal melanoma and melanocytic nevi, and identify what the lesions have in common.
- Identify individuals at high risk who could be targeted for screening for *BAP1* mutations.
- Discuss the role of genetics and genetic counseling.
- Discuss the use of biomarkers for early detection of high risk individuals.
- Discuss early intervention strategies that include therapeutic approaches to treat uveal melanoma and mesothelioma.

## Continuing Education Credits

The Queen's Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Queen's Medical Center designates this live activity for a maximum of **6.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Location & Parking

The conference will be held at The Queen's Conference Center on the campus of The Queen's Medical Center at 1301 Punchbowl Street, Honolulu, Hawaii.

Validated parking will be available in the Queen's Physicians Office Building I. Enter from Lusitana Street. Directions will be sent upon registration.

## Symposium Scientific & Organizing Committee

Michele Carbone, MD, PhD  
*University of Hawaii Cancer Center*

Darlena Chadwick, RN, MSN  
*The Queen's Medical Center*

Giovanni Gaudino, PhD  
*University of Hawaii Cancer Center*

Debra Ishihara Wong, APRN, MN  
*The Queen's Medical Center*

Grace Y. Iwahashi, MPH, CHES  
*The Queen's Medical Center*

Paul T. Morris, MD, FACS  
*The Queen's Medical Center*

Haining Yang, PhD  
*University of Hawaii Cancer Center*

THIRD ANNUAL TRANSLATIONAL CANCER MEDICINE SYMPOSIUM  
Mesothelioma-Melanoma Cancer Syndrome:  
Gene-Environment Interaction?

Registration form

Name \_\_\_\_\_

MD / DO       Researcher       Other: \_\_\_\_\_

Mailing Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_

Daytime Phone \_\_\_\_\_ Fax \_\_\_\_\_

E-mail Address \_\_\_\_\_

**Registration Fee** (The fee covers course materials and lunch.)

**By November 18, 2011**

**After November 18, 2011**

\$ 40

\$ 55

**Method of Payment**

Check or money order payable to: The Queen's Medical Center  
 VISA     Mastercard     American Express     Discover

Cardholder's Name \_\_\_\_\_ Total Payment \$ \_\_\_\_\_

Cardholder mailing address \_\_\_\_\_  
(if different from above)

Card Number \_\_\_\_\_ Card Security ID Code \* \_\_\_\_\_

Signature \_\_\_\_\_ Expiration Date \_\_\_\_\_

*\*3 or 4-digits printed on card or signature strip*

**Please send completed registration form and payment to:**

The Queen's Medical Center  
Office of Continuing Medical Education  
1301 Punchbowl Street  
Honolulu, HI 96813  
Phone: (808) 691-4406; Fax: (808) 691-5040

**Special Needs** - The Queen's Medical Center fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you are in need of accommodation, written notification of any special needs at least one month in advance will help us serve you better.

**Refund** - To receive a refund for the registration fee, cancellation must be made in writing. Refunds will be processed less 20% service fee if made by November 18, 2011. No refunds will be made after that date.

**Cancellation** - This program is subject to cancellation. In the unlikely event that it would have to be cancelled, refund of registration fees will be made in full; however, the sponsor is not responsible for any airfare, hotel or other costs you incur.